Health Boards
A novel new drug for the treatment of psoriasis is about to start Phase 1B clinical trials, ShK-186 is Kineta's® lead clinical stage drug candidate in its Autoimmune program. Originally derived from Stichodactyla helianthus, a Caribbean sea anemone. Kineta’s drug product is manufactured synthetically. Preclinical research demonstrated that ShK-186 is effective in animal models of eight autoimmune diseases including multiple sclerosis and rheumatoid arthritis.
Source: NO LINKS ALLOWED
Source: NO LINKS ALLOWED
Quote:
Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, announced today that the company has opened a Phase 1B proof-of-concept clinical trial for psoriasis using its drug candidate, ShK-186. ShK-186 is a novel, immune-sparing therapeutic in development for a variety of autoimmune diseases. Kineta is planning on initiating an additional clinical trial in patients with psoriatic arthritis in the coming months.
The psoriasis trial is designed to evaluate the effects of biweekly injections of ShK-186 for four weeks in patients with active plaque psoriasis. Patients will be monitored for safety endpoints, assessment of redness, scaling, and lesion thickness, as well as inflammatory biomarker activity in blood and skin biopsy tissue.
“Initiating this trial is another milestone in the clinical development of this novel compound,” said Charles Magness, Kineta’s CEO and President. “Patients with autoimmune diseases desperately need new treatments that effectively address the disease without harmful side effects.”
Source: NO LINKS ALLOWED
Source: NO LINKS ALLOWED